AbbVie 실시간 차트

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

AbbVie news

Tommy Yap 2025 Apr 19, 16:00

Week Ahead: Growth, Inflation, and Consumer Trends in Focus

Forex Indices
Federal Reserve Rate Decision 
Darius Anucauskas 2025 Jan 25, 16:00

Week Ahead: China Is On Holiday, But The BoC, The Fed, And The ECB Will Be Busy With The First 2025 Rate Announcements 

Forex Indices
Magnificent 7 earnings, US and Japan inflation due next week
Neil Wilson 2024 Jul 18, 16:00

Week ahead: Magnificent 7 earnings, 2 key inflation reports

Forex Indices
Wall Street earnings
Neil Wilson 2023 Oct 20, 10:00

Week ahead: Earnings bonanza, ECB decision & US inflation

Forex Indices
Neil Wilson 2023 Jul 21, 00:09

Week ahead: Fed, ECB & BoJ in action

Forex Indices

최신 뉴스

더 보기
Noah Lee 2025 Sep 12, 10:20

US-Japan Joint Statement: Reaffirming Market-Driven Exchange Rates

Emma Rose 2025 Sep 12, 09:20

Goldman Sachs, UBS Raise Gold Price Forecasts for 2025

Noah Lee 2025 Sep 12, 09:20

Albania Appoints AI Minister to Combat Corruption in Public Procurement

Emma Rose 2025 Sep 11, 15:20

Dalio: Gold as a Hedge Against Mounting Debt Risks

Ava Grace 2025 Sep 11, 14:20

Switzerland Proposes US Gold Refinery to Reduce Tariffs

Noah Lee 2025 Sep 11, 14:20

NATO and EU on Edge After Russian Drone Enters Poland: A Critical Test

Liam James 2025 Sep 11, 10:20

Economists Anticipate BOJ Rate Hike in Q4 Amidst Global Uncertainties

Sophia Claire 2025 Sep 11, 10:20

Fed Rate Cut Debate Intensifies: Employment Data Revision Fuels Calls for Action

정보

스프레드

1.37

스프레드(%)

0.6245 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 폐장

금요일

13:31 - 19:59

월요일

13:31-19:59

화요일

13:31-19:59

수요일

13:31-19:59

목요일

13:31-19:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

389031854080

발행 주식 수

1766560000

수익 날짜 (다음)

0000-00-00

배당수익률

2025-11-14

배당락일

2025-10-15

예상 연간 배당금

6.56

예상 연간 배당수익률

0.0298

EPS

2.09

이 상품에 대해 자세히 알아보기

AbbVie AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

latest_education_articles

더 보기
Trustpilot